Home › Compare › AKBIF vs ABBV
AKBIF yields 276.24% · ABBV yields 3.06%● Live data
📍 AKBIF pulled ahead of the other in Year 1
Combined, AKBIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AKBIF + ABBV for your $10,000?
Akebono Brake Industry Co., Ltd. researches, develops, manufactures, and sells brakes, and related components and parts Japan, North America, Europe, and other Asian countries. The company offers disc brake calipers, disc brake pads, disc rotors, drum brake linings, drum brake shoes, wheel cylinders, drum-in-hat brakes, brake drums, sensors, etc. for automobiles; and disc brake calipers, disc brake pads, master cylinders, and others for motorcycles. It also provides brakes for rolling stock, including disc brakes and brake linings for bullet trains, brake linings for regular trains, disc brakes for monorail, brake linings for rolling stock, brake shoes for railroad trains, etc. In addition, the company offers brakes for industrial machinery, such as drum brakes for forklifts, clutch facings for car air conditioner units, brake shoes for elevators, etc., as well as disc brakes for wind turbine generators and rough terrain cranes. Further, it provides sensor products comprising accelerometers, angular rate sensors, and sensor clusters; vehicle behavior detection and wireless portable vibration measurement devices; and inclinometers, concrete filing detectors, light emitting inclination sensors/pockets, and earthquake detectors for long-wave seismic motors. The company was formerly known as Akebono Sekimen Kogyo Co., Ltd. and changed its name to Akebono Brake Industry Co., Ltd. in 1960. Akebono Brake Industry Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.
Full AKBIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.